Haohai Biotech: 36,000 H-Shares Repurchased; Outstanding Share Count Unchanged at 226.13 Million

Bulletin Express

May 15

Shanghai Haohai Biological Technology Co., Ltd. (Haohai Biotech) disclosed that it bought back 36,000 H-shares on 15 May 2026 via the Hong Kong Stock Exchange at prices ranging from HKD 21.78 to HKD 22.04 per share, spending HKD 0.79 million in aggregate. The repurchased shares are designated for cancellation and remain in treasury pending that process.

• Issued share capital unchanged: As of 15 May 2026, Haohai Biotech’s issued share capital (excluding treasury shares) stood at 226.13 million, comprising 190.20 million A-shares and 35.93 million H-shares.

• Cumulative buy-backs awaiting cancellation: Since 23 March 2026, the company has repurchased 1.15 million H-shares at prices between HKD 21.55 and HKD 22.87, all of which remain uncancelled.

• Repurchase mandate utilisation: Under the mandate granted on 10 June 2025 allowing up to 3.91 million H-share buy-backs, Haohai Biotech has repurchased 3.75 million shares to date, equivalent to 9.58 % of the outstanding shares at the time of authorisation.

• Moratorium on new issues: In line with Hong Kong listing rules, the company is restricted from issuing new shares or selling treasury shares until 14 June 2026.

No changes were recorded in the company’s A-share capital during the period under review, and the total of 3.85 million A-shares held in treasury remains unchanged.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1178965226"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1178965226\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1178965226?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 17:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178965226","market":"us","top_or_hot":-1,"title":"Haohai Biotech: 36,000 H-Shares Repurchased; Outstanding Share Count Unchanged at 226.13 Million","media":"Bulletin Express","content":"<p>Shanghai Haohai Biological Technology Co., Ltd. (Haohai Biotech) disclosed that it bought back 36,000 H-shares on 15 May 2026 via the Hong Kong Stock Exchange at prices ranging from HKD 21.78 to HKD 22.04 per share, spending HKD 0.79 million in aggregate. The repurchased shares are designated for cancellation and remain in treasury pending that process.</p>\n<p>• Issued share capital unchanged: As of 15 May 2026, Haohai Biotech’s issued share capital (excluding treasury shares) stood at 226.13 million, comprising 190.20 million A-shares and 35.93 million H-shares.</p>\n<p>• Cumulative buy-backs awaiting cancellation: Since 23 March 2026, the company has repurchased 1.15 million H-shares at prices between HKD 21.55 and HKD 22.87, all of which remain uncancelled.</p>\n<p>• Repurchase mandate utilisation: Under the mandate granted on 10 June 2025 allowing up to 3.91 million H-share buy-backs, Haohai Biotech has repurchased 3.75 million shares to date, equivalent to 9.58 % of the outstanding shares at the time of authorisation.</p>\n<p>• Moratorium on new issues: In line with Hong Kong listing rules, the company is restricted from issuing new shares or selling treasury shares until 14 June 2026.</p>\n<p>No changes were recorded in the company’s A-share capital during the period under review, and the total of 3.85 million A-shares held in treasury remains unchanged.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Haohai Biotech: 36,000 H-Shares Repurchased; Outstanding Share Count Unchanged at 226.13 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHaohai Biotech: 36,000 H-Shares Repurchased; Outstanding Share Count Unchanged at 226.13 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-15 17:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Haohai Biological Technology Co., Ltd. (Haohai Biotech) disclosed that it bought back 36,000 H-shares on 15 May 2026 via the Hong Kong Stock Exchange at prices ranging from HKD 21.78 to HKD 22.04 per share, spending HKD 0.79 million in aggregate. The repurchased shares are designated for cancellation and remain in treasury pending that process.</p>\n<p>• Issued share capital unchanged: As of 15 May 2026, Haohai Biotech’s issued share capital (excluding treasury shares) stood at 226.13 million, comprising 190.20 million A-shares and 35.93 million H-shares.</p>\n<p>• Cumulative buy-backs awaiting cancellation: Since 23 March 2026, the company has repurchased 1.15 million H-shares at prices between HKD 21.55 and HKD 22.87, all of which remain uncancelled.</p>\n<p>• Repurchase mandate utilisation: Under the mandate granted on 10 June 2025 allowing up to 3.91 million H-share buy-backs, Haohai Biotech has repurchased 3.75 million shares to date, equivalent to 9.58 % of the outstanding shares at the time of authorisation.</p>\n<p>• Moratorium on new issues: In line with Hong Kong listing rules, the company is restricted from issuing new shares or selling treasury shares until 14 June 2026.</p>\n<p>No changes were recorded in the company’s A-share capital during the period under review, and the total of 3.85 million A-shares held in treasury remains unchanged.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06826","symbol_name":"昊海生物科技","start_time":0,"source_url":"","article_id":"1178965226","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178965226","pubTimestamp":1778837002,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Haohai Biological Technology Co., Ltd. (Haohai Biotech) disclosed that it bought back 36,000 H-shares on 15 May 2026 via the Hong Kong Stock Exchange at prices ranging from HKD 21.78 to HKD...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06826":"昊海生物科技"},"translate_title":"昊海生科：回购3.6万股H股；流通股数量不变，为2.2613亿股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06826":1},"content_text":"Shanghai Haohai Biological Technology Co., Ltd. (Haohai Biotech) disclosed that it bought back 36,000 H-shares on 15 May 2026 via the Hong Kong Stock Exchange at prices ranging from HKD 21.78 to HKD 22.04 per share, spending HKD 0.79 million in aggregate. The repurchased shares are designated for cancellation and remain in treasury pending that process.\n• Issued share capital unchanged: As of 15 May 2026, Haohai Biotech’s issued share capital (excluding treasury shares) stood at 226.13 million, comprising 190.20 million A-shares and 35.93 million H-shares.\n• Cumulative buy-backs awaiting cancellation: Since 23 March 2026, the company has repurchased 1.15 million H-shares at prices between HKD 21.55 and HKD 22.87, all of which remain uncancelled.\n• Repurchase mandate utilisation: Under the mandate granted on 10 June 2025 allowing up to 3.91 million H-share buy-backs, Haohai Biotech has repurchased 3.75 million shares to date, equivalent to 9.58 % of the outstanding shares at the time of authorisation.\n• Moratorium on new issues: In line with Hong Kong listing rules, the company is restricted from issuing new shares or selling treasury shares until 14 June 2026.\nNo changes were recorded in the company’s A-share capital during the period under review, and the total of 3.85 million A-shares held in treasury remains unchanged.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}